{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:55:43Z","timestamp":1781456143051,"version":"3.54.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Brain metastases in advanced thyroid cancer may be underrecognized due to lack of routine brain imaging. We characterized the clinical and molecular features, risk factors, and survival outcomes of patients with non-anaplastic follicular cell-derived thyroid carcinoma (FCDTC) with brain metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included patients with advanced non-anaplastic FCDTC treated in the Medical Oncology Department at Princess Margaret Cancer Centre between 2007 and 2022. Clinicopathologic and treatment data were extracted from electronic records, and all tumors underwent targeted next-generation sequencing. Risk factors for brain metastasis were assessed using logistic regression, and overall survival was analyzed with Kaplan-Meier and Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 187 patients with advanced non-anaplastic FCDTC, 32 (17%) were diagnosed with brain metastases. Dedicated brain imaging was performed in 56% of patients, and most metastases (78%) were asymptomatic and incidentally detected. Lung metastases were associated with higher risk of developing brain metastases (aOR 8.27, 95% CI 1.87-36.46). ARID2 mutations were enriched in patients with brain metastases (9% vs 1%, P\u2009=\u2009.02). Survival did not differ between patients with and without brain metastases. Patients with brain metastases who had an ECOG performance status \u22652 (aHR 6.30, 95% CI 1.61-24.64) or \u22654 brain metastases (aHR 4.92, 95% CI 1.45-16.64) had worse survival. Molecular alterations were not predictive of survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Brain metastases occurred more frequently than previously reported. Lung metastases were associated with higher risk of developing brain metastases, and performance status and lesion number were associated with survival. These findings support consideration of brain metastasis screening in advanced thyroid cancer and may inform future prognostic and treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag211","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:40:09Z","timestamp":1779968409000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical and molecular features associated with the presence of brain metastases and survival in patients with advanced thyroid cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9042-0150","authenticated-orcid":false,"given":"Carly C","family":"Barron","sequence":"first","affiliation":[{"name":"Endocrine Oncology Site Group, Princess Margaret Cancer Centre , Toronto, ON M5G 2M9,","place":["Canada"]},{"name":"Division of Medical Oncology, Department of Medicine, University of Toronto , Toronto, ON M5S 1A8,","place":["Canada"]},{"name":"Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network , Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais Baccili Cury","family":"Megid","sequence":"additional","affiliation":[{"name":"Dr. L\u00e9on-Richard Oncology Centre, Vitalit\u00e9 Health Network , Moncton, NB E1C 8X3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangqing","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University Health Network , Toronto, ON M5G 1X6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijithan","family":"Sugumar","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto , Toronto, ON M5S 3H2,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ladak","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network , Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruz","family":"Mesci","sequence":"additional","affiliation":[{"name":"Endocrine Oncology Site Group, Princess Margaret Cancer Centre , Toronto, ON M5G 2M9,","place":["Canada"]},{"name":"Department of Radiation Oncology, University of Toronto , Toronto, ON M5T 1P5,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Yan","sequence":"additional","affiliation":[{"name":"Endocrine Oncology Site Group, Princess Margaret Cancer Centre , Toronto, ON M5G 2M9,","place":["Canada"]},{"name":"Department of Radiation Oncology, University of Toronto , Toronto, ON M5T 1P5,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Lukovic","sequence":"additional","affiliation":[{"name":"Endocrine Oncology Site Group, Princess Margaret Cancer Centre , Toronto, ON M5G 2M9,","place":["Canada"]},{"name":"Department of Radiation Oncology, University of Toronto , Toronto, ON M5T 1P5,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika K","family":"Krzyzanowska","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, University of Toronto , Toronto, ON M5S 1A8,","place":["Canada"]},{"name":"Division of Medical Oncology & Hematology, Sunnybrook Odette Cancer Centre , Toronto, ON M4N 3M5,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M","family":"Sawka","sequence":"additional","affiliation":[{"name":"Endocrine Oncology Site Group, Princess Margaret Cancer Centre , Toronto, ON M5G 2M9,","place":["Canada"]},{"name":"Division of Endocrinology, University Health Network and University of Toronto , Toronto, ON M5G 2C4,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0469-2801","authenticated-orcid":false,"given":"Ozgur","family":"Mete","sequence":"additional","affiliation":[{"name":"Endocrine Oncology Site Group, Princess Margaret Cancer Centre , Toronto, ON M5G 2M9,","place":["Canada"]},{"name":"Department of Pathology, University Health Network , Toronto, ON M5G 2C4,","place":["Canada"]},{"name":"Department of Laboratory Medicine & Pathobiology, University of Toronto , Toronto, ON M5G 2C4,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-0715","authenticated-orcid":false,"given":"Lucy X","family":"Ma","sequence":"additional","affiliation":[{"name":"Endocrine Oncology Site Group, Princess Margaret Cancer Centre , Toronto, ON M5G 2M9,","place":["Canada"]},{"name":"Division of Medical Oncology, Department of Medicine, University of Toronto , Toronto, ON M5S 1A8,","place":["Canada"]},{"name":"Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network , Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2026061313491659200_oyag211-B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026061313491659200_oyag211-B2","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"key":"2026061313491659200_oyag211-B3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1089\/thy.2013.0061","article-title":"Brain metastases from thyroid carcinoma: a retrospective study of 21 patients","volume":"24","author":"Henriques de Figueiredo","year":"2014","journal-title":"Thyroid"},{"key":"2026061313491659200_oyag211-B4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10585-023-10208-8","article-title":"Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer","volume":"40","author":"Wolff","year":"2023","journal-title":"Clin Exp Metastasis"},{"key":"2026061313491659200_oyag211-B5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40463-020-00469-8","article-title":"Patient and tumor factors contributing to distant metastasis in well-differentiated thyroid cancer: a retrospective cohort study","volume":"49","author":"Khan","year":"2020","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"2026061313491659200_oyag211-B6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1210\/jcem-67-3-501","article-title":"Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables","volume":"67","author":"Ruegemer","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061313491659200_oyag211-B7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/RLU.0000000000002618","article-title":"Thyroid cancer brain metastasis: survival and genomic characteristics of a large tertiary care cohort","volume":"44","author":"Osborne","year":"2019","journal-title":"Clin Nucl Med"},{"key":"2026061313491659200_oyag211-B8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1210\/js.2018-00241","article-title":"Brain metastases from differentiated thyroid carcinoma: prevalence, current therapies, and outcomes","volume":"3","author":"Gomes-Lima","year":"2019","journal-title":"J Endocr Soc"},{"key":"2026061313491659200_oyag211-B9","doi-asserted-by":"publisher","first-page":"1073274820914661","DOI":"10.1177\/1073274820914661","article-title":"Radioactive iodine therapy in patients with thyroid carcinoma with distant metastases: a SEER-Based study","volume":"27","author":"Li","year":"2020","journal-title":"Cancer Control"},{"key":"2026061313491659200_oyag211-B10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ijsu.2018.06.001","article-title":"Outcomes and prognostic factors in thyroid cancer patients with cranial metastases: a retrospective cohort study of 4,683 patients","volume":"55","author":"Hong","year":"2018","journal-title":"Int J Surg"},{"key":"2026061313491659200_oyag211-B11","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1089\/thy.2024.0240","article-title":"Brain metastases in differentiated thyroid cancer: clinical presentation, diagnosis, and management","volume":"34","author":"Prinzi","year":"2024","journal-title":"Thyroid"},{"key":"2026061313491659200_oyag211-B12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.eprac.2023.08.003","article-title":"Survival outcomes of advanced thyroid cancer enriched in brain metastases following treatment with small molecule inhibitors","volume":"29","author":"Wu","year":"2023","journal-title":"Endocr Pract"},{"key":"2026061313491659200_oyag211-B13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1089\/thy.2023.0709","article-title":"Survival prognostication in patients with differentiated thyroid cancer and distant metastases: a SEER Population-Based study","volume":"34","author":"Chen","year":"2024","journal-title":"Thyroid"},{"key":"2026061313491659200_oyag211-B14","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1177\/10507256251372639","article-title":"Prognostic factors in thyroid cancer patients with brain metastases: a systematic review and meta-analysis","volume":"35","author":"Salim","year":"2025","journal-title":"Thyroid"},{"key":"2026061313491659200_oyag211-B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s43856-024-00445-7","article-title":"Estimating the risk of brain metastasis for patients newly diagnosed with cancer","volume":"4","author":"Miccio","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"2026061313491659200_oyag211-B16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/COC.0000000000000230","article-title":"Brain metastases at presentation in patients with non-small cell lung cancer","volume":"41","author":"Waqar","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"2026061313491659200_oyag211-B17","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1200\/JCO.2009.24.6314","article-title":"Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer","volume":"28","author":"Graesslin","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026061313491659200_oyag211-B18","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1200\/JCO.19.01508","article-title":"Cumulative incidence and predictors of CNS metastasis for patients with American joint committee on cancer 8th edition stage III melanoma","volume":"38","author":"Haydu","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026061313491659200_oyag211-B19","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.22.00520","article-title":"Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update","volume":"40","author":"Ramakrishna","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026061313491659200_oyag211-B20","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N Engl J Med"},{"key":"2026061313491659200_oyag211-B21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","article-title":"Current approaches to the management of brain metastases","volume":"17","author":"Suh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2026061313491659200_oyag211-B22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"2026061313491659200_oyag211-B23","doi-asserted-by":"publisher","first-page":"L7","DOI":"10.1530\/ERC-17-0453","article-title":"8th edition of the AJCC\/TNM staging system of thyroid cancer: what to expect (ITCO#2)","volume":"25","author":"Lamartina","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2026061313491659200_oyag211-B24","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.3747\/co.26.5235","article-title":"OCTANE (Ontario-wide cancer targeted nucleic acid evaluation): a platform for intraprovincial, national, and international clinical data-sharing","volume":"26","author":"Malone","year":"2019","journal-title":"Curr Oncol"},{"key":"2026061313491659200_oyag211-B25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13073-016-0364-2","article-title":"Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the princess Margaret IMPACT\/COMPACT trial","volume":"8","author":"Stockley","year":"2016","journal-title":"Genome Med"},{"key":"2026061313491659200_oyag211-B26","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ijrobp.2007.06.074","article-title":"A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database","volume":"70","author":"Sperduto","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026061313491659200_oyag211-B27","doi-asserted-by":"publisher","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2026061313491659200_oyag211-B28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","article-title":"NCCN guidelines\u00ae insights: melanoma: cutaneous, version 2.2024","volume":"22","author":"Swetter","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"2026061313491659200_oyag211-B29","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2026061313491659200_oyag211-B30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026061313491659200_oyag211-B31","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026061313491659200_oyag211-B32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082323","article-title":"Clinical course from diagnosis to death in patients with well-differentiated thyroid cancer","volume":"12","author":"Park","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026061313491659200_oyag211-B33","doi-asserted-by":"publisher","first-page":"e0154739","DOI":"10.1371\/journal.pone.0154739","article-title":"The largest known survival analysis of patients with brain metastasis from thyroid cancer based on prognostic groups","volume":"11","author":"Choi","year":"2016","journal-title":"PLoS One"},{"key":"2026061313491659200_oyag211-B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132371","article-title":"Brain metastases from thyroid carcinoma: prognostic factors and outcomes","volume":"16","author":"Esmaeilzadeh","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026061313491659200_oyag211-B35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11060-010-0175-z","article-title":"Stereotactic radiosurgery in the management of brain metastases from primary thyroid cancers","volume":"98","author":"Bernad","year":"2010","journal-title":"J Neurooncol"},{"key":"2026061313491659200_oyag211-B36","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1210\/jcem.82.11.4386","article-title":"Prognosis and treatment of brain metastases in thyroid carcinoma","volume":"82","author":"Chiu","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061313491659200_oyag211-B37","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1089\/thy.2021.0628","article-title":"Radiotherapy for brain metastases from thyroid cancer: an institutional and national retrospective cohort study","volume":"32","author":"Blomain","year":"2022","journal-title":"Thyroid"},{"key":"2026061313491659200_oyag211-B38","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1089\/thy.2020.0947","article-title":"Stereotactic radiosurgery for differentiated thyroid cancer brain metastases: an international, multicenter study","volume":"31","author":"Bunevicius","year":"2021","journal-title":"Thyroid"},{"key":"2026061313491659200_oyag211-B39","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.18632\/oncotarget.27686","article-title":"Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases","volume":"11","author":"In","year":"2020","journal-title":"Oncotarget"},{"key":"2026061313491659200_oyag211-B40","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41698-023-00471-z","article-title":"Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases","volume":"7","author":"In","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"2026061313491659200_oyag211-B41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040731","article-title":"Integrative genomic analyses of Patient-Matched intracranial and extracranial metastases reveal a novel brain-Specific landscape of genetic variants in driver genes of malignant melanoma","volume":"13","author":"V\u00e1raljai","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026061313491659200_oyag211-B42","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1038\/s41598-024-54136-3","article-title":"ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes","volume":"14","author":"Akinjiyan","year":"2024","journal-title":"Sci Rep"},{"key":"2026061313491659200_oyag211-B43","doi-asserted-by":"publisher","first-page":"886","DOI":"10.18632\/oncotarget.355","article-title":"ARID2: a new tumor suppressor gene in hepatocellular carcinoma","volume":"2","author":"Zhao","year":"2011","journal-title":"Oncotarget"},{"key":"2026061313491659200_oyag211-B44","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.jhep.2016.12.026","article-title":"ARID2 modulates DNA damage response in human hepatocellular carcinoma cells","volume":"66","author":"Oba","year":"2017","journal-title":"J Hepatol"},{"key":"2026061313491659200_oyag211-B45","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/ijc.27900","article-title":"Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma","volume":"132","author":"Manceau","year":"2013","journal-title":"Int J Cancer"},{"key":"2026061313491659200_oyag211-B46","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/s41388-020-01537-z","article-title":"Exome sequencing identifies ARID2 as a novel tumor suppressor in early-onset sporadic rectal cancer","volume":"40","author":"Bala","year":"2021","journal-title":"Oncogene"},{"key":"2026061313491659200_oyag211-B47","doi-asserted-by":"publisher","first-page":"110637","DOI":"10.1016\/j.celrep.2022.110637","article-title":"Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma","volume":"39","author":"Carcamo","year":"2022","journal-title":"Cell Rep"},{"key":"2026061313491659200_oyag211-B48","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026061313491659200_oyag211-B49","doi-asserted-by":"publisher","first-page":"E754","DOI":"10.1210\/jc.2013-3734","article-title":"TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas","volume":"99","author":"Melo","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061313491659200_oyag211-B50","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","article-title":"Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial","volume":"27","author":"Subbiah","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag211\/68431912\/oyag211.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag211\/68431912\/oyag211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag211\/68431912\/oyag211.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:10:03Z","timestamp":1781453403000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag211\/8698037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag211","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,29]]},"article-number":"oyag211"}}